Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
A-SPINE Asia Co., Ltd. (6758.TWO)
New Taipei City, TW
A-SPINE Asia Co., Ltd. functions as a medical device enterprise, specializing in the entire cycle of research, development, production, and worldwide distribution of spinal implants and surgical instruments. The company's market presence spans numerous countries, including Taiwan, China, the Philippines, Australia, New Zealand, Iran, Vietnam, Indonesia, Spain, Trinidad, and Sri Lanka. Their product catalog features a variety of spinal stabilization systems, such as solutions for cervical anterior fixation, alongside thoracic and lumbar fixation devices. Additionally, A-SPINE Asia provides a comprehensive range of interbody fusion systems, encompassing ACDF, PLIF, TLIF, and ALIF cages. Its offerings further extend to balloon kyphoplasty and vertebral body replacement devices. Beyond its own manufactured products, the firm also acts as a distributor for a selection of imported orthopedic medical equipment. Established in 2001, A-SPINE Asia Co., Ltd. is based in New Taipei City, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.07% | -8.83% | -24.27% | -29.88% | -28.01% | -28.10% | -13.94% | -25.95% | -44.64% | -68.09% | -68.09% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Devices: +11.2%+10.8% Q4'25: +5.8% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+80.7% ★ Q4'25: -31.3% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%+5.2% ★ Q4'25: +10.9% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%+4.9% Q4'25: +4.3% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%+5.0% ★ Q4'25: +8.4% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%+0.1% Q4'25: +0.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×3.75× Q4'25: 2.04× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-05 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-04 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive team data is not available for this company yet.
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6758.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
